Primitive AML progenitors from most CD34⁺ patients lack CD33 expression but progenitors from many CD34⁻ AML patients express CD33

References

• Sutherland HJ, Blair A, Zapf RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood 1996; 87: 4754–61
   PubMed Web of Science ®Google Scholar
• Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukaemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34 + /CD71−/HLA-DR−. Blood 1998; 92: 4325–35
   PubMed Web of Science ®Google Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730–6
   PubMed Web of Science ®Google Scholar
• Terstappen LWMM, Huang S, Safford M, et al. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38− progenitor cells. Blood 1991; 77: 1218–27
   PubMed Web of Science ®Google Scholar
• Sutherland HJ, Eaves CJ, Eaves AC . Differential expression of antigens on cells that initiate haemopoiesis in long-term human marrow culture. In: Knapp W, et al, Dorken B, Gilks WR. (editors). Leukocyte typing IV. White cell differentation antigens. Oxford University Press, 1989;910–2.
   Google Scholar
• Sutherland HJ, Eaves CJ, Eaves AC, et al. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 1989; 74: 1563–70
   PubMed Web of Science ®Google Scholar
• Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukaemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997; 89: 3104–12
   PubMed Web of Science ®Google Scholar
• Reuss-Borst MA, Buhring HJ, Schmidt H, et al. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. Leukemia 1994; 8: 258–63
   PubMed Web of Science ®Google Scholar
• Di Noto R, Lo Pardo C, Schiavone EM, et al. Stem cell factor receptor (c-kit, CD117) is expressed on blast cells from most immature types of acute myeloid malignancies but is also a characteristic of a subset of acute promyelocytic leukemia. Br J Haematol 1996; 92: 562–4
   PubMed Web of Science ®Google Scholar
• Osawa M, Hanada KI, Hamada H, et al. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 1996; 273: 242–5
   PubMed Web of Science ®Google Scholar
• Bhatia M, Bonnet D, Murdoch B, et al. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med 1998; 4: 1038–45
   PubMed Web of Science ®Google Scholar
• Terpstra W, Prins A, Ploemacher RE, et al. Long–term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukaemia. Blood 1996; 87: 2187–94
   PubMed Web of Science ®Google Scholar
• Vercauteren SM, Sutherland HJ. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 2001; 3: 449–59
   Web of Science ®Google Scholar
• Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–6
   PubMed Web of Science ®Google Scholar
• Tanimoto M, Scheinberg DA, Cordon-Cardo C, et al. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 1989; 3: 339–48
   PubMed Web of Science ®Google Scholar
• Andrews RG, Takahashi M, Segal GM, et al. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 1986; 68: 1030–5
   PubMed Web of Science ®Google Scholar
• Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 1989; 169: 1721–31
   PubMed Web of Science ®Google Scholar
• Dinndorf PA, Andrews RG, Bnejamin D, et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986; 67: 1048–53
   PubMed Web of Science ®Google Scholar
• Baer MR, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implication for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 2001; 97: 3574–80
   PubMed Web of Science ®Google Scholar
• Legrand O, Perrot JY, Baudard M, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96: 870–7
   PubMed Web of Science ®Google Scholar
• de Nully Brown P, Jurlander J, Pedersen-Bjergaard J, et al. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia. Leuk Res 1997; 21: 985–95
   Google Scholar
• Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–54
   PubMed Web of Science ®Google Scholar
• Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002; 16: 1627–36
   PubMed Web of Science ®Google Scholar
• Verlinden SF, van Es HH, van Bekkum DW. Serial bone marrow sampling for long-term follow up of human hematopoiesis in NOD/SCID mice. Exp Hematol 1998; 26: 627–30
   PubMedGoogle Scholar
• Fraser C, Eaves CJ, Kalousek DK. Fluorodeoxyuridine synchronization of hemopoietic colonies. Cancer Genet Cytogenet 1987; 24: 1–6
   PubMed Web of Science ®Google Scholar
• Lau YF, Huang JC, Dozy AM , et al. A rapid screening test for antenatal sex determination. Lancet 1984;14–6.
   Google Scholar
• Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645–8
   PubMed Web of Science ®Google Scholar
• Wouters R, Lowenberg B. On the maturation order of AML cells: a distinction on the basis of self-renewal properties and immunologic phenotypes. Blood 1984; 63: 684–9
   PubMed Web of Science ®Google Scholar
• Sabbath KD, Ball ED, Larcom P, et al. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest 1985; 75: 746–53
   PubMed Web of Science ®Google Scholar
• Kabral A, Bradstock KF, Grimsley P, et al. Immunophenotype of clonogenic cells in myeloid leukaemia. Leuk Res 1988; 12: 51–9
   PubMed Web of Science ®Google Scholar
• Guan Y, Ralph S, Hogge DE. Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia. Exp Hematol 2002; 30: 721–8
   Google Scholar
• Matsui H, Takeshita A, Naito K, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia 2002; 16: 813–9
   PubMed Web of Science ®Google Scholar
• Ailles LE, Gerhard B, Kawagoe H, et al. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999; 94: 1761–72
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1994–9
   Google Scholar